1st Quarter - Report
HOSPIRA, INC. for HOSPIRA INC
Firm
Client
Income
—
Expenses
$240,000
Expense method
A: Lobbying Disclosure Act definitions
What was lobbied
2 issue areas, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
PL 111-148 Patient Protection and Affordable Health Care Act provisions relating to biosimilar products. Issues relateing to generic drug labeling and drug pedigree.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JILL DOWELL | — |
| JULIANA REED | — |
Budget/Appropriations BUD
H.R.933 Consolidated and Further Continuing Appropriations Act relating to FDA biosimilar user fees; S.Con. Res.8 - provisions relating to ACA medical device tax.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JILL DOWELL | — |
| JULIANA REED | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.